Related Experiment Video

Updated: Aug 9, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

The genetic tyrosinemias

C Ronald Scott1

  • 1Department of Pediatrics, University of Washington, Seattle, WA 98195, USA. crscott@u.washington.edu

American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
|April 8, 2006
PubMed

Insights

Genetic tyrosinemias are rare metabolic disorders caused by enzyme deficiencies, leading to tyrosine accumulation. Early diagnosis and dietary management, alongside specific treatments like NTBC for Type I, are crucial for patient outcomes.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Genetic tyrosinemias are inherited metabolic disorders characterized by tyrosine accumulation.
  • These conditions result from specific enzyme deficiencies, impacting various body systems.

Purpose of the Study:

  • To provide a comprehensive overview of the genetic tyrosinemias, including their genetic basis, clinical manifestations, diagnostic approaches, and therapeutic strategies.
  • To highlight the distinct features and management of Tyrosinemia Type I, Type II, and Type III.

Main Methods:

  • Review of existing literature on genetic tyrosinemias.
  • Analysis of diagnostic markers including plasma amino acid chromatography and urine organic acid analysis.
  • Discussion of therapeutic interventions such as dietary modifications and pharmacotherapy.

Main Results:

  • Tyrosinemia Type I (FAH deficiency) presents with severe liver disease and neurological issues, with succinylacetone as a key diagnostic marker.
  • Tyrosinemia Type II (TAT deficiency) is characterized by ocular and skin lesions.
  • Tyrosinemia Type III (4-HPPD deficiency) is rare and associated with neurological deficits.
  • Elevated tyrosine and specific metabolites in plasma and urine are key diagnostic indicators.

Conclusions:

  • Genetic tyrosinemias require prompt diagnosis through biochemical analysis and enzyme/molecular studies for definitive confirmation.
  • Management involves a low-phenylalanine and tyrosine diet for all types, with NTBC being a critical treatment for Tyrosinemia Type I.
  • Understanding the specific type of tyrosinemia is essential for targeted therapeutic interventions and improved patient prognosis.

More Related Videos

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Epistasis01:39

Epistasis

In addition to multiple alleles at the same locus influencing traits, numerous genes or alleles at different locations may interact and influence phenotypes in a phenomenon called epistasis. For example, rabbit fur can be black or brown depending on whether the animal is homozygous dominant or heterozygous at a TYRP1 locus. However, if the rabbit is also homozygous recessive at a locus on the tyrosinase gene (TYR), it will have an unshaded coat that appears white, regardless of its TYRP1...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Epistasis Analysis01:09

Epistasis Analysis

Although Mendel chose seven unrelated traits in peas to study gene segregation, most traits involve multiple gene interactions that create a spectrum of phenotypes. When the interaction of various genes or alleles at different locations influences a phenotype, this is called epistasis. Epistasis often involves one gene masking or interfering with the expression of another (antagonistic epistasis). Epistasis often occurs when different genes are part of the same biochemical pathway. The...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...